利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.032 秒)

    Delivery of highly lipophilic agents via medical devices
    1.
    发明申请
    Delivery of highly lipophilic agents via medical devices 审中-公开
    通过医疗器械递送高度亲脂性的药剂

    公开(公告)号：US20060240070A1

    公开(公告)日：2006-10-26

    申请号：US11386587

    申请日：2006-03-22

    申请人： Keith Cromack ,  John Toner ,  Sandra Burke ,  Richard Krasula ,  Lewis Schwartz

    发明人： Keith Cromack ,  John Toner ,  Sandra Burke ,  Richard Krasula ,  Lewis Schwartz

    IPC分类号： A61F2/20 ,  A61K38/17 ,  A61K48/00

    CPC分类号： A61L31/16 ,  A61L27/34 ,  A61L27/54 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L2300/00 ,  A61L2300/416 ,  A61L2300/45 ,  A61L2300/604

    摘要： An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

    摘要翻译： 一种用于递送与医疗装置相关联的亲脂剂的装置和系统，包括：医疗装置，能够穿透体腔的第一亲脂性试剂，其中第一亲脂性试剂的转移系数为统计学上显着的 至少约5,000，其中所述第一亲脂性试剂与所述医疗装置相关联，其中所述第一亲脂性试剂/医疗装置放置在所述体腔附近，并且其中治疗有效量的所述第一亲脂性试剂被递送至 课程。 此外，本发明涉及一种用于提高受试者通畅的方法，包括将医疗装置放置在体腔中，用于治疗和/或预防相邻疾病或维持体腔通畅。

    Methods of administering rapamycin analogs with anti-inflammatories using medical devices
    7.
    发明申请
    Methods of administering rapamycin analogs with anti-inflammatories using medical devices 失效
    使用医疗器械用抗炎药管理雷帕霉素类似物的方法

    公开(公告)号：US20070224240A1

    公开(公告)日：2007-09-27

    申请号：US11548827

    申请日：2006-10-12

    申请人： John Toner ,  Sandra Burke ,  Keith Cromack ,  Matthew Mack

    发明人： John Toner ,  Sandra Burke ,  Keith Cromack ,  Matthew Mack

    IPC分类号： A61F2/00

    CPC分类号： A61L31/16 ,  A61F2/91 ,  A61F2250/0067 ,  A61L2300/416 ,  A61L2300/45

    摘要： A medical device comprising a supporting structure capable of including or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may include one or more therapeutic agents or substances, with the carrier including a coating on the surface thereof, and the coating including the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to, This drug can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.

    摘要翻译： 一种医疗装置，其包括能够包含或支撑药学上可接受的载体或赋形剂的支持结构，所述载体或赋形剂可以包含一种或多种治疗剂或物质，所述载体在其表面上包括涂层，并且所述包衣包含治疗 物质，例如药物。 适用于本发明的医疗装置的支撑结构包括但不限于冠状支架，外周支架，导管，动静脉移植物，旁路移植物和用于脉管系统中的药物递送球囊。 适用于本发明的药物包括但不限于：该药物可与另一药物组合使用，包括选自抗增殖剂，抗血小板剂，抗炎剂，抗血栓形成剂 ，细胞毒性药物，抑制细胞因子或趋化因子结合的药物，细胞去分化抑制剂，抗脂血症药，基质金属蛋白酶抑制剂，细胞抑制药物或这些药物的组合。

    COMPOSITIONS AND METHODS FOR ADMINISTERING DEXAMETHASONE WHICH PROMOTE HUMAN CORONARY ARTERY ENDOTHELIAL CELL MIGRATION
    9.
    发明申请
    COMPOSITIONS AND METHODS FOR ADMINISTERING DEXAMETHASONE WHICH PROMOTE HUMAN CORONARY ARTERY ENDOTHELIAL CELL MIGRATION 审中-公开
    用于治疗人类冠状动脉内皮细胞迁移的DEXAMETHASONE的组合物和方法

    公开(公告)号：US20080004694A1

    公开(公告)日：2008-01-03

    申请号：US11752093

    申请日：2007-05-22

    申请人： Matthew Mack ,  Sandra Burke ,  John Toner ,  Keith Cromack

    发明人： Matthew Mack ,  Sandra Burke ,  John Toner ,  Keith Cromack

    IPC分类号： A61F2/06

    CPC分类号： A61L31/16 ,  A61L2300/43 ,  A61L2300/606

    摘要： A drug-eluting endoprosthesis is configured for inhibiting restenosis and thrombosis, and for promoting healing of a lesion in a body of a subject. Such an endoprosthesis includes at least a supporting structure and a therapeutically effective amount of dexamethasone is disposed thereon. The therapeutically effective amount of dexamethasone allows for the drug to elute from the supporting structure so as to obtain a concentration of dexamethasone that is sufficient for inhibiting restenosis and/or inhibiting thrombosis. Also, the therapeutically effective amount of dexamethasone is substantially devoid of inhibiting cell migration such that migrating cells promote healing of the lesion. Additionally, the therapeutically effective amount of dexamethasone induces cell migration such that migrating cells promote healing of the lesion.

    摘要翻译： 药物洗脱内用假体被配置用于抑制再狭窄和血栓形成，并且用于促进受试者体内的损伤的愈合。 这种内用假体至少包括支撑结构，治疗有效量的地塞米松位于其上。 地塞米松的治疗有效量允许药物从支持结构中洗脱，以获得足以抑制再狭窄和/或抑制血栓形成的地塞米松浓度。 此外，地塞米松的治疗有效量基本上没有抑制细胞迁移，使得迁移的细胞促进损伤的愈合。 此外，治疗有效量的地塞米松诱导细胞迁移，使得迁移的细胞促进病变的愈合。